RecruitingPhase 3Drug trialEfficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and DiabetesThe primary objective of this study is to demonstrate that KAI-9531 subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)